On the other hand, improved metabolic health could reduce atrial remodeling, a known contributor to atrial fibrillation
News provided by CVS Health May 28, 2026, 06:45 ET Expanded GLP-1 options for members create a path to sustainable coverage of these important medications WOONSOCKET, R.I., May 28, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members including the reintroduction of Zepbound (tirzepatide) as a covered medication
Chronic exposure to nonylphenol induces oxidative stress and liver damage in male zebrafish (Danio rerio): Mechanistic insight into cellular energy sensors, lipid accumulation and immune modulation
By tailoring treatment to each patients unique needs, we make care more personal, accessible, and effective leading to stronger long-term health outcomes